To determine the current approach to stem cell transplantation (SCT) in centres which treat predominantly paediatric patients, a questionnaire was sent to 67 centres known by the EBMT registry to perform SCT mainly in children. Fifty-five centres from 19 countries responded. Forty centres (75%) started their transplantation activities between 1980 and 1992. Median number of transplants/centre was 95 (range 8-400). Median number of transplants/centre/year was 18 (range 5-85). On average, there was one physician responsible for seven SCT/year while one nurse was involved for a median of 1.7 SCT/year. Median four rooms/centre (range 1-17) were available for paediatric SCT. The most common isolation facilities were rooms with high efficiency particulate air filtration (HEPA). Eighty-two percent (45/55) of the centres performed allogeneic as well as autologous SCT, while 5% (three centres) offered exclusively allogeneic SCT and 13% (seven centres) used only autologous stem cell rescue. Stem cell source for allogeneic SCT was bone marrow in 87%, peripheral blood (PB) in 10% and umbilical cord blood in 3%. Donors were HLA matched related in 57%, mismatched related in 13%, and matched unrelated in 30% of allogeneic SCT. PB was the most commonly used stem cell source for autologous SCT (48%), followed by BM (41%) and the two together (11%). Data analysis revealed substantial differences in protective care, stem cell processing and transplantation procedures within the centres, irrespective of the country, centre size and transplant type. Keywords: stem cell transplantation; children; isolation rooms; staff; bone marrow harvesting; blood cell support Allogeneic (allo) and autologous (auto) stem cell transplants (SCT) are performed increasingly in children with malignancies, as well as with congenital or acquired haema-
topoietic disorders. 1 Many are being treated in paediatric SCT centres. To date there has been little knowledge of their size, equipment and their specific paediatric treatment modalities. Overall SCT activity has been summarised in the annual transplantation activity reports of the EBMT 2 and the IBMTR registries. 3 However, these reports were based on data derived from transplants in both paediatric and adult patients and do not give information on the number of children with SCT within the EBMT. Therefore, the newly established EBMT working party on paediatric diseases was interested to learn how many patients of the centres that treat predominantly children had been transplanted to date and to find out the actual yearly capacity for performing transplants. They also wanted to gain an impression on the isolation facilities, the methods for stem cell processing and transfusion policy. Analysis of the different topics should help to reveal differences between the individual procedures and could form a basis for defining treatment and stem cell processing standards, and make it possible for others to profit from these data. This report focuses on the overall and annual transplantation activities, different requirements for paediatric stem cell transplantation centres, some specific procedures (ie stem cell harvesting, TBI and intensive care) and strategies for blood cell support in children.
Patients and methods
In October 1995 a questionnaire consisting of about 400 questions was mailed to 67 centres known by the EBMT registry to perform predominantly SCT in children. The final analysis was performed in August 1997 after additional inclusion of late responses. The questionnaire covered the following topics: total number of transplanted patients, number of annual transplants, stem cell sources, indication for SCT in children, currently practised supportive care modalities, GVHD prophylaxis and treatment standards, available room facilities and medical staff requirements. Standard supportive care modalities have been published previously, 4 while GVHD prophylaxis and treatment and comparison of different treatment standards between allogeneic and autologous SCT are in preparation.
Median values and range were calculated for metric variables. To reflect the individual transplantation experience of each centre, the answers to each topic were multiplied with the total sum of transplanted patients per centre and expressed in weighted percent (% w ). The responding centres were divided into subgroups according to the number of paediatric transplantations/year (Ͻ20 transplantations/year vs у = 20 transplantations/year). Comparisons of subgroups were done by Wilcoxon two-sample test for quantitative variables 5 and by 2 test or Fisher's exact-test 6 for categorical data. The data on transplantations activity per year refer to the years 1995 and 1996, respectively.
Results
Fifty-five centres from 19 countries answered the questionnaire (appendix). Collectively these centres have treated 7045 patients. The majority of responses came from Germany, Italy, Spain, UK, France, Sweden and Switzerland. From some countries all paediatric SCT centres could be included in the analysis (eg Austria, Czech Republic, Finland, The Netherlands, Poland, Slovak Republic).
Transplantation activity
The first successful allogeneic SCT in Europe was performed at Leiden (The Netherlands) in a child with SCID in 1968. 7 Nine of the 55 responding centres (17%) started transplantation procedures before 1980, the majority, ie 40/55 (75%), started between 1980 and 1992, while 4/55 centres (8%) started only after 1992. Two centres did not specify the onset of their activity.
Transplantation experience of the individual centres ranged widely with cumulative numbers of SCT between eight and 400 (median 95), reflecting the different time span of SCT activity, as well as the different numbers of transplants per year. The median number of transplants/ centre/year was 18 (range 5-85), with eight (15%) of the centres performing less than 10, 19 (36%) 10-20, 10 (19%) 20-30 and 16 (30%) more than 30; two answers were missing. In four European countries (Belgium, Poland, Slovak Republic, Switzerland) none of the reporting centres transplanted more than 20 paediatric patients per year. The most important indices of transplantation activity are presented in Table 1 .
Patient age
Patient age limits varied among the centres. Forty percent of the centres performed SCT in infants under 6 months of age. Fifty percent indicated as lower age limit 6 or 12 months, 4% transplanted only patients older than 1 year, and 6% older than 2 years. The upper age limit of the transplanted patients was 14, 15 or 16 years in 31% of the centres, 17 or 18 years in 46%, and 30 years in 23% of the centres. This means that some of the centres, although caring predominantly for paediatric patients performed SCT also in adolescents, and exceptionally in young adults. 
Transplant type
Eighty two percent (45/55) of the centres performed allogeneic as well as autologous SCT, while 5% (three centres) exclusively offered allogeneic SCT and 13% (seven centres) used only autologous SC rescue. The analysis showed a slight predominance of allogeneic (10 SCT/centre/year, range 1-65) over autologous (8 SCT/centre/year, range 1-30) accounting for a total of 638 allogeneic and 514 autologous SCT per year.
Allogeneic SCT
The median transplant frequency was 10 (range 1-65) allogeneic SCT/centre/year.
The most common stem cell source was bone marrow (87%), followed by peripheral blood stem cells (PBSC) (10%) while cord blood transplantation was still rare with only 3% of the total allogeneic SCT at the time of evaluation. While Germany, Austria and Spain had an augmented interest in allogeneic PBSCT from cytokine-stimulated donors, experience with umbilical cord blood transplants accumulated in France, Italy and Spain.
HLA-identical family members still dominated as donors (57%). Thirty percent of the patients were transplanted from unrelated donors, while HLA-mismatched family donors were chosen in 13% of the cases. (Table 2) .
Autologous SCT
In the autologous SCT setting less than 10 patients/ centre/year underwent the procedure in almost two-thirds (57%) of the centres. Only 11% performed more than 20 SCT/year and 32% did between 10 and 19 stem cell reinfusions/year. On average eight autologous SCT/centre/year were performed. PBSC started to outrun bone marrow as stem cell source. The yearly distribution incidence is as follows: 250 SCT were performed with PBSC (most frequently in Germany, Italy and France), 209 with BM (most frequent in Italy, Russia, Spain) and 55 with stem cells from both PB and BM (most frequent in Czech Republic, Italy, Sweden) per year (Table 3) .
433 Table 2 Stem cell sources and donor types 
NC = nucleated cells; MNC = mononuclear cells; CFU = colonyforming units.
Transplantation procedures
Bone marrow harvesting for allogeneic transplantation: Allogeneic SCT were performed in 48/55 centres. Bone marrow as allogeneic stem cell source was used in all but one clinic. The majority of them (95.8%) always harvested allogeneic bone marrow under general anaesthesia. Only one centre (2.1%) claimed to perform bone marrow collection only under local/lumbar anaesthesia, while one centre (2.1%) applied both anaesthesia options.
Processing of allogeneic bone marrow:
When bone marrow processing was indicated before transplantation, most centres preferred centrifugation techniques, followed by mechanic separation and less often sedimentation procedures (Table 4) .
Allogeneic PBSC collection:
There was one centre performing allogeneic transplantation exclusively with PBSC, 23 centres (49%) performed PBSC collection in some donors, while 24 centres (51%) did not collect allogeneic PBSC. Most PBSC collections for allo SCT were performed in Germany, Spain and UK. During the observation time no allogeneic PBSCT were reported from Switzerland, Belgium, Poland, Russia, The Netherlands, Finland, Greece and Denmark. The frequency of PBSC collection was not related to the size of the centre. 
Infusion of stem cells:
The maximum volume of unmanipulated bone marrow cells ranged between 10 and 40 ml/kg body weight (median 15 ml/kg). The median infusion speed was 21 ml/kg/h (range 5-45 ml/kg/h). The estimated number of cells per kilogram of recipient body weight needed for transplantation is summarised in Table 3 .
Substitution of blood products (Table 5 ): All centres except one gave routine support with packed red blood cells. The most common indication for substitution was a haemoglobin level under 8 g/dl.
The criterion for platelet substitution was a platelet count below 20 × 10 9 /l for 65% of the centres. No significant differences were observed with respect to indications for blood product substitution between different transplantation types (allogeneic vs autologous), large and small centres or between the participating countries.
All but two centres irradiated all infused blood products. The removal of leucocytes by filters was performed for all patients in 46 centres (84.2% w ) and sometimes in seven centres (15.8% w ). One centre which performed allogeneic and autologous SCT did not routinely remove leucocytes by filters nor was irradiation of blood products performed. Blood products from CMV-negative donors were given for all patients in 19 centres (34.0% w ), for some patients in 24 centres (46.5% w ) and never in nine centres (19.5% w ). Single donors for blood products were available for all patients in 12 centres (23.5% w ), for some patients in 28 centres (54.5% w ), and never in 13 centres (22% w ). No differences were observed between the various centre sizes or participating countries.
Transplantation-associated facilities
Staff resources: On average there was one physician available for seven SCT/year (range 1-45 patients) apart from the medical head of the transplant unit. One nurse was concerned with a median of 1.7 SCT/year (range 0.2-7.5). Comparing large and small centres and the different countries no significant differences were detected between the number of employed physicians and nurses.
Pre-and post-transplant care was the responsibility of the transplant unit team in 88.9% of the centres. Psycho-social support provided by a specialised team was offered to patients and relatives in 46 centres (85.2%). Out-patient service within the transplant centre was available in 78% of the responding centres. The need for continuity between in-and out-patient care in SCT is obviously widely accepted, and thus no significant differences with respect to out-patient services could be observed between centres performing below or over 20 SCT/year, between countries or between centres with dominating allogeneic or autologous SCT.
Room requirements: The number of rooms available for paediatric SCT varied in different centres between one and 17, with a median of four rooms/centre. Patient numbers varied in the rooms available, ie 1-13 patients per room and year (median five patients/room/year). The median isolation time of a patient in a sterile unit was 30 days (range 9-128 days). Most centres (67%) started with isolation care with the beginning of conditioning, another 29% started between days −1 and +1 and 4% started later (eg with the onset of granulocytopenia after autologous SCT). No statistically significant differences were found between centres that perform either allogeneic or autologous SCT, between the participating countries or between large and small centres.
The most common type of isolation rooms were high efficiency particulate air filtration (HEPA) rooms accounting for 38% of all isolation facilities, followed by private rooms and laminar air flow (LAF) units (28% each), and others (6%). Some centres only had LAF rooms (12.5%). The country with the most centres offering exclusively LAF rooms was Germany. Nineteen percent of the centres had exclusively HEPA rooms. The country which predominantly used HEPA units was Italy. Seventeen percent of the centres only had private rooms. Switzerland was the country most frequently offering private rooms only. The other centres (51.5%) had combinations of different rooms types. The most frequent combinations were HEPA + LAF and private + LAF rooms, each accounting for 12.5% of the centres. The different isolation facilities did not correspond with the predominant transplant type (allo, auto) or with stem cell sources used. For example, centres equipped with HEPA and LAF rooms isolated almost the same quota of allogeneic and autologous patients. Most centres made the decision to end the isolation of allogeneic and autologous patients dependent on the ANC (Ͼ500/l) and on the control of infections. For allogeneic transplant patients control of GVHD was also taken into account. There was no difference between large and small centres.
Total body irradiation:
Five centres did not perform any TBI (1.7% w ). Two centres (1% w ) performed only single dose TBI, 45 centres (86% w ) always fractionated TBI, and three centres (11.3% w ) performed both. The number of fractions varied between two and 12 (median six fractions). The median dose rate was 6 cGy/min (range 3-200 cGy/min). The lowest age limit for TBI varied between 0 and 5 years (median 2 years). Lung shielding was performed in 40 centres, in one centre it was not applied, and 14 centres did not answer the question. The median dose for lung shielding was 9 Gy (6-11 Gy). The alternative for TBI was always busulfan-containing regimens.
Intensive care: Intensive care procedures were provided in some centres within the transplant unit. Twenty centres (33.0% w ) performed haemodialysis in the BMT unit, with no difference between small and large centres or between countries. Assisted ventilation was performed in 11 centres (22.2% w ) in the BMT unit with no difference between large and small centres or between countries.
Indications for transferring a patient to a specialised intensive care unit are summarised in Table 5 .
Discussion
The EBMT registry recently gave detailed annual reports on the total number of SCT per year, the disease categories and the stem cell sources applied. 2, 8 The Working Party for Inborn Errors have collected data concerning patients who received BMT for immunodeficiencies, osteopetrosis and metabolic disorders. 9 However, no results have been published on the total or annual number of children who underwent allogeneic or autologous SCT in different centres or on the demand for room and personnel capacity.
Although not all known paediatric transplant centres replied to the questionnaire, the high percentage of replies from 17 European countries are likely to represent the majority of paediatric centres in Europe. Some teams outside Europe (Australia, Israel) which have a close connection with the EBMT also contributed to the survey. Countries reporting to the EBMT registry but without separate units for children are not included in this analysis.
It is intriguing that the first successful allogeneic SCT in Europe was performed in a child with SCID who is still alive and well. However, it took more than a decade before SCT became a commonly used procedure in paediatric patients. One-fourth of the paediatric transplant centres have a long history of SCT and can be described as experts in SCT with a cumulative number of more than 200 transplants and 30 transplants/year. However, the median number of SCT/centre/year was 18. According to the EBMT recommendations 10 a single centre should perform at least 20 transplant procedures per year. Hence, this criterion is not met by half of the paediatric centres. This does not apply exclusively to centres that transplant autologous but also to centres that offer allogeneic SCT. It is the opinion of the working party on paediatric diseases, that the role of these 'small' centres is particularly important if they are the only ones in their region young patients can turn to. It would be very useful to find out if the centres have free capacity for transplantation. The working party would then propose that children are assigned preferably to these centres within their countries. The centres that performed predominantly ABMT in solid tumours are likely to treat both extreme age limits, ie very young patients with neuroblastoma as well as adolescents or young adults with Ewing tumours. In contrast to the EBMT report 11 this analysis revealed that more allogeneic transplants than autologous stem cell re-infusions were performed in children. The main reason for the higher number of allogeneic SCT in children is the higher incidence of acute leukaemia. Another explanation implies the rare occurrence of lymphoma, breast cancer and myeloma in children. These represent the main indications for autologous SCT in adults.
The predominant autologous stem cell source was peripheral blood stem cells although harvesting methods for very young children were established over the past years. 12 It was demonstrated that autologous transplantation of PBSCs is associated with more rapid haematological recovery than is bone marrow transplant after high-dose chemotherapy for solid tumours or lymphomas. Furthermore, global costs are lower and cost-effectiveness ratios are better with PBSC transplantation. 13 The predominant donor type for children was HLA matched siblings. However, the total of 30% for unrelated donor transplants was higher than reported in the EBMT report for UD-SCT performed in Europe during the observation time.
14 Cord blood transplantation might give additional perspectives for those children for whom a suitable related or unrelated bone marrow donor could not be identified. 15 PBSC are gaining increasing acceptance as an alternative to bone marrow (BM)-derived stem cells for allografting from HLA-identical sibling donors and HLA mismatch family donors, respectively. 16, 17 In some countries stimulation of healthy stem cell donors with cytokines is not allowed. This may be the reason for regional differences in the use of allogeneic stem cells. Some centres consider transplantation of allogeneic PBSC if the donor is an adult or for second transplant, if graft failure occurred after first BMT.
Bone marrow processing requires filtration to remove small clots, bone fragments, fat cells and fibrin. Most centres add a further step of bone marrow manipulation to separate red cells, mature granulocytes and plasma to avoid ABO incompatibilities and volume overload in small children. 18 There were wide variations in the methodology which reflected the different patients being treated, local conditions and personal preferences. The most commonly used techniques were centrifugation and mechanical separation, while sedimentation methods were less commonly used. Standards for bone marrow and other stem cell processing methods, as well as evaluation procedures, should be established and reviewed to ensure timely and sustained engraftment after various ablative regimens.
It could be demonstrated that a high number (Ͼ3.64 or 4.2 × 10 8 /kg recipient's body weight) of allogeneic bone marrow cells is associated with improved haematological recovery, lower transplant-related mortality and better leukaemia-free survival. 19, 20 When autologous stem cells are used the administration of chemotherapy and growth factors before PBSC harvesting seems to accelerate haematologic reconstitution. 21 Patients who received at least 3 × 10 6 /kg CD34 + cells achieved granulocyte reconstitution on day 11 after reinfusion (range [8] [9] [10] [11] [12] [13] [14] [15] and an unsupported platelet count of 25 × 10 9 /l on day 14 (range 12-180), significantly earlier than patients who received fewer cells (P Ͻ 0.001). 22 Thus, efforts should be made to transplant high stem cell doses (Ͼ3 × 10 6 /kg recipient's body weight) both in the allogeneic and autologous setting.
There were substantial differences in the maximum transfusion volume of unmanipulated bone marrow cells which ranged between 10 and 40 ml/kg body weight (median 15 ml/kg). Regardless of the age of a child this amount can be given safely when the patient is haemodynamically stable. 23 However, the infusion speed needs to be adapted to the cardiovascular situation of the patient to avoid pulmonary oedema.
Although nearly all centres reported the routine support of red cells and platelets, transfusion policy was heterogeneous and should result in common transfusion standards which can be accepted by the majority of centres including criteria for blood cell transfusion, leukocyte inactivation to avoid third-party GVHD and prophylaxis for CMV infection in transplanted children.
Great differences were found between the number of physicians and nurses involved in the treatment of transplant patients. This could not be clearly explained by the annual transplantation procedures but might partly reflect the difference in responsibilities carried by the medical staff (ie preand post-transplant care, administration, documentation and science). Some discrepancies might have their origin in the incomplete staff of some centres and the necessity to share personnel with non-transplant units due to discontinuous transplantation activity in some smaller centres.
Different efforts have been made to protect neutropenic patients from both intrinsic and extrinsic pathogens, ranging from single room isolation to LAF units. 24 LAFs with high efficiency particulate air filtration still appear to be the best means of protection against aspergillosis 25 but were not available for the majority of patients. They would probably be allocated to patients who have the highest risk for severe fungal infections, ie patients with protracted neutropenia and immunosuppression. There are no comparative trials describing the benefit of different isolation rooms within the different transplantation categories. Thus, prospective evaluation of the various isolation practices with respect to patient comfort, outcome and costs would be of importance.
TBI is currently used as part of the conditioning regimen in SCT with various radiation doses, fractionation scheduling and dose rate. The most important late effects after TBI include growth impairment, hypothyroidism, delayed puberty, gonadal failure, cataracts, lung and renal function abnormalities and development of secondary cancer. The side-effects of TBI appear to be aggravated when given as a single dose, after prophylactic cranial irradiation and in very young children. 26 In this survey, the attitude towards TBI was clearly in favour of fractionated TBI but the procedure itself varied in many details which might influence its efficacy, toxicity and late effects. Thus, irradiation methodology including dose rate, number of fractions, lung shielding or compensation and age limits for TBI should be discussed and standardised. A more uniform approach would be of value in the implementation of international multi-centre trials. When busulfan is substituted for TBI ascertaining plasma busulfan levels may result in a reduction of adverse effects or decreased rejection and relapse incidence, respectively. 27 Providing intensive care within the SCT unit was not a prerequisite for the majority of centres, although some procedures were performed in isolation rooms. The most common indication for transferring severely ill children to a specialised ICU was respiratory failure or multi-organ dysfunction. On the other hand, fluid imbalances observed in renal insufficiency or VOD were mostly handled in the transplantation unit. In view of the growing experience in various countries, it could be important to work out guidelines to specify intensive care status after SCT.
In summary, this survey should form the basis for consensus discussions within the participating EBMT members to constitute recommendations for stem cell transplantation procedures in children. Common treatment standards will be necessary to obtain comparable results on paediatric stem cell transplantation as well as to keep this intensive treatment procedure as efficient as possible.
